← Back to headlines
Capricor Stock Falls Following Report of Potential Deramiocel Rejection
Capricor Therapeutics' stock experienced a decline after a report indicated a potential rejection of its drug Deramiocel, impacting investor confidence.
20 Aug, 14:55 — 20 Aug, 14:55
Sources
Showing 1 of 1 sources
